An interventional study of Cryoneurolysis and Sham Cryoneurolysis in Rib Fractures, Rib Fracture Multiple and Rib; Fracture, With Flail Chest, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Traumatic rib fractures (i.e., broken ribs caused by a physical injury) are common and very painful. They also often lead to serious complications, more time spent in hospital, and can even lead to death. Even after rib fractures have healed, they can lead to long-term pain and a lower quality of life.
A technology called cryoneurolysis, which acts to freeze nerves causing pain using a small tool which can turn very cold, is a promising new way to manage rib fracture pain. This study is a test with a small number of people to see if it is feasible to use this technology for patients with rib fractures. If this is successful, we will recruit more people for a larger study to see if cryoneurolysis, along with standard pain control techniques, is better at stopping pain, compared to just the normal techniques alone. Participants in our study will be asked to rate their pain, and record pain medications that they take for 3 months after their pain procedure.
More than 100,000 people a year suffer from traumatic rib fractures. Pain from rib fractures impairs the ability to inspire deeply and cough effectively, predisposing patients to severe, potentially life threatening complications and increased healthcare costs. For many patients, this pain can also persist long after the acute injury has healed, delaying recovery and reducing quality of life.
Current pain interventions, including multimodal analgesia and local anesthetic-based nerve blocks, are useful, but are limited by a short duration of effectiveness, and/or risk of complications. Cryoneurolysis (CN) is a new method to control pain which acts to freeze intercostal nerves (ICNs) associated with fractured ribs using a handheld device. This freezing action causes neurons to undergo Wallerian degeneration distally from the site of ablation and thus exhibit an extended but reversible block.
This study is a single-site, randomized, pilot study to assess the feasibility of recruitment, randomization, and protocol adherence of providing cryoneurolysis for patients with traumatic rib fractures. Secondary data from the pilot trial designed to assess the effectiveness of the intervention (pain scores, opioid usage, etc.) will be included in the analysis of the full trial if feasible. The objective of the full trial is to demonstrate that cryoneurolysis of ICN, in addition to standard analgesic practice, provides superior, prolonged analgesia.
Participants (individuals aged 18-85, with 3-8 unilateral traumatic rib fractures) will be randomized 1:1 in blocks of 4, stratified by number of rib fractures (> 4 or ≤4) and the presence/absence of flail segment, to receive the current standard of practice for rib fractures (multimodal analgesia and erector spinae plane (ESP) catheter infusion) with or without the addition of CN. Participants in the standard care group will receive a sham CN procedure to maintain blinding.
All participants (both groups) will receive standard of care analgesia. Specifically, an ultrasound-guided ESP catheter will be placed as per standard protocols. 20cc of 0.5% ropivacaine and 1% lidocaine will be injected through the catheter, followed by a basal infusion of 2 cc/hr of 0.2% ropivacaine (to maintain catheter patency) with an on demand patient controlled regional anesthesia (PCRA) dose of 10cc 0.2% ropivacaine available hourly until patient has met criteria for APS discharge or pain is controlled such that PCRA use is \< 2 boluses over 12 hrs and NRS \< 3 with deep breathing and coughing.
Standard multimodal analgesia including Tylenol 1000mg QID, Celebrex 200mg BID (or ketorolac 7.5 QID), Pregabalin 50mg BID, and/or PRN oral hydromorphone (1-4mg) will also be provided. Additional analgesics include intravenous ketamine at a dose of 0.1-0.2 mg/kg/hr of lean body weight in the event of consistent NRS pain scores > 6, and up to 0.05 mg/kg of intravenous midazolam for anxiolysis and 1mcg/kg of intravenous fentanyl for comfort during positioning, as required.
Participants will remain in the study for 3 months from the date of the block procedure. They will be followed daily while in hospital and using a pain diary following discharge (weekly pain scores and daily opioid usage). Additionally, follow-ups will be completed at 1h, 24h, 48h, 1 week, 1 month, and 3 months post block procedure.
126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.
This study's planned enrollment of 24 is below the median of 60 across 92 interventional studies indexed under Rib Fractures.
Browse Rib Fractures studies →Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to all standard of care analgesia treatments, CN will be performed on the ICN of each broken rib using the Iovera CN device and Generation 2 Iovera tip under ultrasound guidance.
Procedure: Cryoneurolysis
Participants in the control group will receive all standard of care analgesia treatments as well as sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding.
Procedure: Sham Cryoneurolysis
Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
Number of participants randomized over an 8 month period
Goal of 3 participants per month for 8 months
Time frame: Entire pilot study (approximately 8 months)
Number of participants able to adhere to the protocol
Goal of \> 90%
Time frame: Entire pilot study (approximately 8 months + 3 month follow-up)
Number of participants able to adhere to the follow-up
Goal of \> 90%
Time frame: 3 month follow-up
Rate of Adverse events
Ensure no adverse events (short or long term) associated with CN
Time frame: 3 month follow-up
Pain Severity during deep inspiration 24 hours post ESP catheter placement
Pain measured using Numeric Pain Rating Scale
Time frame: 24 hours post placement of ESP catheter
Time to discontinuation of ESP catheter
Based on when patient has met criteria for APS discharge or pain is controlled such that PCRA use is \< 2 boluses over 12 hrs and NRS \< 3 with deep breathing and coughing
Time frame: Until ESP catheter removal (usually < 7 days)
ESP catheter use
Cumulative volume of local anesthetic solution used via ESP catheter patient controlled reginal analgesia
Time frame: Until ESP catheter removal (usually < 7 days)
Opioid consumption in hospital and after discharge
Determined from medical records (in-hospital) and via a daily pain diary (post-discharge). Calculated in Oral Morphine Equivalents.
Time frame: Daily for 90 days after block placement
Pain Intensity at 1 and 3 months
As measured using Numeric Pain Rating Scale (0-10) , at rest and during deep inspiration
Time frame: 1 and 3 month follow-ups
Oxygen requirements
Room air oxygen saturation (SpO2) and requirement for supplementary O2 to maintain SpO2 \> 92%
Time frame: Pre-intervention, post intervention, then daily until discharge
Pulmonary Function Testing
FVC
Time frame: Pre-intervention, post intervention, then daily until discharge
Pulmonary Function Testing
FEV1
Time frame: Pre-intervention, post intervention, then daily until discharge
Pulmonary Function Testing
Peak Inspiratory flow
Time frame: Pre-intervention, post intervention, then daily until discharge
Pulmonary Function Testing
Peak Expiratory Flow
Time frame: Pre-intervention, post intervention, then daily until discharge
Length of Stay in hospital
Hospital discharge date
Time frame: Date of admission to date discharge
Length of Stay on acute pain service (APS)
Criteria include on oral meds without continuous regional analgesia or intravenous opioids
Time frame: Date of admission to date of discharge from acute pain service
Time to achieve discharge criteria for isolated chest injury
Criteria include on oral meds without continuous regional analgesia, chest tube out and chest well evacuated (e.g. no evidence of retained hemothorax), and no supplemental O2
Time frame: Date of admission until discharge criteria met
Patient satisfaction
Patient satisfaction assessed using Patients' Global Impression of Change (PGIC) scale
Time frame: 48 post block procedure, and 1 week, 1 month and 3 month follow-ups
Incidence of chronic rib fracture pain
As assessed using Brief Pain Inventory (BPI) questionnaire
Time frame: 3 month follow-up
Adverse events
Adverse events to be recorded include: local anesthetic complications, catheter related complications (clotting, migration), procedural complications (pneumothorax, bleeding, infection), and neurological disturbances (dysesthesia, hyperalgesia, allodynia) in area of rib fracture
Time frame: until 3 month follow-up
Pain Intensity
As measured using NRS-11, at rest and during deep inspiration
Time frame: 1h and 48h, post block placement, daily in hospital, weekly post discharge and at 1 week follow-up
Plan to share: Yes — De-identified participant-level data will be made available upon reasonable request to study PI following publication of full trial results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: This is a pilot trial and full inferential analysis will not be conducted until completion of the full trial. As such, data will be available following publication of the primary results of the subsequent full trial.
Access criteria: Data and supporting information will be made available following reasonable request directly to study PI.
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.
Of 41 non-industry interventional studies with no phase under Rib Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's planned 26 months is above that.
Counting every sponsor, half of 41 studies reached it within 23 months; a quarter within 15 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sunnybrook Health Sciences Centre →